奕瑞电子科技集团股份有限公司 董事会薪酬与考核委员会 关于公司 2026 年员工持股计划相关事项的核查意见 奕瑞电子科技集团股份有限公司（以下简称"公司"）董事会薪酬与考核委员 会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点 的指导意见》（以下简称"《指导意见》"）、《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）、《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》（以下简称"《自律监管指引第 1 号》"）等相关法 律、法规及规范性文件和《奕瑞电子科技集团股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，对《公司 2026 年员工持股计划（草案）》（以下简称 "《持股计划（草案）》"或"本持股计划"）进行了核查，发表核查意见如下： 一、公司不存在《公司法》《证券法》《指导意见》《上市规则》《自律监 管指引第 1 号》等有关法律、法规及规范性文件规定的禁止实施员工持股计划的 情形。 四、本持股计划拟定的持有人均符合《指导意见》及有关法律、法规及规范 性文件规定的持有人 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2026-003 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 奕瑞电子科技集团股份有限公司 第三届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 2026 年 1 月 23 日，奕瑞电子科技集团股份有限公司（以下简称"公司"或"奕 瑞科技"）以现场及通讯方式召开了第三届董事会第二十四次会议（以下简称"本 次会议"），会议通知已于 2026 年 1 月 16 日以电子邮件形式发出。本次会议由董 事长 Tieer Gu 先生主持，会议应出席董事 9 人，实际出席并表决的董事 9 人。本 次会议的召开及表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 等相关法律、法规以及《奕瑞电子科技集团股份有限公司章程》（以下简称"《公 司章程》"）的有关规定。 二、董事会会议审议情况 （一）审议通过了《关于修订<董事和高级管理人员薪酬管理制度>的议案 ...

Core Viewpoint - The company plans to implement an employee stock ownership plan (ESOP) for 2026, targeting up to 150 participants including directors and executives [1] Group 1: Employee Stock Ownership Plan Details - The funding for the ESOP will come from employees' legal salaries and other sources [1] - The stock will be sourced from a repurchase account and purchases in the secondary market [1] - The duration of the ESOP will not exceed 36 months, with a lock-up period of 12 months [1] Group 2: Financial Aspects - The total funding amount for the ESOP will not exceed 100 million yuan [1] - The estimated share price for the plan is 119.79 yuan per share, allowing for a maximum of 834,800 shares to be held, which represents no more than 0.39% of the total share capital [1] Group 3: Approval Process - As of the date of the legal opinion issuance, the company has completed part of the internal review process, but the plan still requires approval from the shareholders' meeting [1]

Core Viewpoint - Yirui Technology is positioned as a leading domestic X-ray detector manufacturer, benefiting from a recovery in medical tenders and a resurgence in lithium battery capital expenditures, indicating a turning point in its main business performance [1] Group 1: Company Overview - Yirui Technology is one of the few global manufacturers that master all major core technologies in digital X-ray detectors [1] - The company has entered the supply chains of global giants such as GE, Siemens, and Philips, continuously leading domestic substitution [1] - The company maintains strong profitability due to its comprehensive solution offerings and vertical supply chain integration, which create core advantages under high technical barriers [1] Group 2: Growth Potential - The binding with Shiya Technology allows Yirui Technology to enter the high-growth AI glasses market, which is expected to bring new growth drivers for the company [1] - The OLED backplane processing business is anticipated to accelerate performance contributions [1] Group 3: Investment Rating - The initial coverage of Yirui Technology has been given a "strong buy" investment rating [1]

Company and Industry Summary Company: Yirui Technology (奕瑞科技) Key Points - **Performance Growth Outlook**: Yirui Technology is expected to achieve high growth in revenue and net profit in Q4 2025 due to a low base effect, with an overall performance growth trend anticipated to be front-loaded in the first half and accelerate in the latter half of the year [1] - **2026 Projections**: The new core components and solutions/technical services business are expected to continue the high growth momentum from the previous year, with significant orders for silicon-based OLED micro-display modules from its affiliate, Shiya Technology, likely to enhance overall revenue and net profit [1] - **Sample and Production Deliveries**: In 2025, Yirui Technology plans to deliver samples and a small quantity of mass-produced products to Shiya Technology, with expected revenue not exceeding 100 million RMB, compared to the previous year's actual amount of 3.39 million RMB [1] Company: Shiya Technology (视涯科技) Key Points - **Financial Commitment**: Shiya Technology has agreed to pay Yirui Technology a guarantee amount not exceeding 1 billion RMB [2] - **Industry Position**: Shiya Technology operates in the VR/AR (augmented reality) glasses sector, providing silicon-based OLED micro-display modules to specific clients [2] - **Growth Strategy**: The company is transitioning from being an expert in X-ray flat panel detectors to a multi-dimensional core component supplier, with new core components such as high-voltage generators and CT detectors expected to create new growth avenues [2] - **Market Expansion**: Shiya Technology is accelerating its overseas market expansion, which is anticipated to further enhance growth potential [2] - **Financial Projections**: For 2025-2027, the expected net profit attributable to shareholders is projected to be 630 million, 770 million, and 946 million RMB, representing year-on-year growth rates of 35.35%, 22.33%, and 22.81% respectively. The price-to-earnings ratios (PE) based on the closing price on January 16, 2026, are projected to be 39X, 32X, and 26X [2] - **Funding for Expansion**: Shiya Technology plans to raise 1.45 billion RMB for the construction of X-ray vacuum devices and comprehensive solution projects, which will add significant production capacity [2]

Investment Rating - The report gives a "Strong Buy" investment rating for the company [1][11]. Core Insights - The company is a leading domestic X-ray detector manufacturer, expected to benefit from a recovery in medical tenders and a resurgence in capital expenditure in the lithium battery sector, marking a turning point in its main business performance [2][8]. - The company is entering the high-growth AI glasses market through a partnership with Visionary Technology, which is anticipated to open new growth avenues [3][11]. Company Overview - The company is recognized as a leader in the domestic X-ray detector market, with a projected global market share of 20% by 2024 [18]. - It specializes in digital X-ray detectors, high-voltage generators, combination X-ray sources, and tubes, with applications spanning medical, industrial, and dental fields [18][19]. Main Business - The company is transitioning from a single supplier of X-ray detectors to a comprehensive supplier of X-ray solutions, enhancing product value and customer loyalty [8][27]. - Short-term recovery is expected due to improved downstream demand, with a projected revenue growth of 20% in 2025 [10][11]. - Long-term growth is driven by expanding product offerings, industry applications, and market penetration, with a focus on increasing overseas business, which is expected to account for 34% of revenue by mid-2025 [8][11]. New Business Ventures - The company is entering the high-growth AI glasses sector, leveraging its capabilities in OLED micro-displays through a partnership with Visionary Technology [3][9]. - The global XR device shipment is projected to grow significantly, with a CAGR of 55.5% from 2025 to 2029, indicating a robust market opportunity [8][11]. Financial Data and Valuation - Revenue projections for 2025, 2026, and 2027 are estimated at 22.01 billion, 34.56 billion, and 44.54 billion yuan, respectively, with corresponding net profits of 6.25 billion, 7.87 billion, and 10.08 billion yuan [10][11]. - The company maintains a strong financial position with a return on equity (ROE) of 9.0% and a debt-to-asset ratio of 46.4% [4].

Core Viewpoint - The medical device sector experienced a decline of 1.58% on January 16, with Kangzhong Medical leading the losses, while the Shanghai Composite Index fell by 0.26% and the Shenzhen Component Index decreased by 0.18% [1]. Group 1: Market Performance - The medical device sector's stocks showed mixed performance, with notable gainers including Huakang Clean (20.01% increase) and Yirui Technology (4.60% increase) [1]. - Conversely, Kangzhong Medical saw a significant drop of 8.60%, followed by Huada Zhizao with a decline of 6.61% [2]. - The overall trading volume in the medical device sector was substantial, with Huakang Clean achieving a transaction amount of 707 million yuan [1]. Group 2: Capital Flow - The medical device sector experienced a net outflow of 1.395 billion yuan from major funds, while retail investors contributed a net inflow of 1.42 billion yuan [2]. - Specific stocks like Huakang Clean had a net inflow of 58.17 million yuan from major funds, while retail investors showed a net outflow of 46.88 million yuan [3]. - The capital flow dynamics indicate a shift in investor sentiment, with retail investors actively participating despite the overall sector decline [2][3].

Core Viewpoint - Yirui Technology's stock has shown a positive trend with a year-to-date increase of 8.66% and a recent uptick of 2.02% on January 6, 2025, indicating strong market interest and performance in the medical device sector [1]. Group 1: Stock Performance - As of January 6, 2025, Yirui Technology's stock price reached 109.87 yuan per share, with a trading volume of 2.24 billion yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 23.232 billion yuan [1]. - The stock has experienced a 6.67% increase over the last five trading days and an 8.41% increase over the last 20 trading days, while it has seen a decline of 5.01% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Yirui Technology reported a revenue of 1.549 billion yuan, reflecting a year-on-year growth of 14.22%, and a net profit attributable to shareholders of 471 million yuan, which is a 20.61% increase compared to the previous year [2]. - The company has distributed a total of 789 million yuan in dividends since its A-share listing, with 557 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Yirui Technology increased to 8,011, marking a 14.61% rise, while the average number of circulating shares per person decreased by 12.74% to 24,992 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is a new entrant holding 3.802 million shares, while Huabao Zhongzheng Medical ETF has exited the list [3]. Group 4: Business Overview - Yirui Technology, established on March 7, 2011, and listed on September 18, 2020, specializes in the research, production, sales, and service of digital X-ray detectors, with the main revenue sources being detector sales (81.21%), core component sales (7.66%), solution/technical service income (5.89%), accessory sales (4.57%), and rental income (0.66%) [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device sector, and is associated with various concepts including medical devices, mid-cap stocks, margin financing, security, and share buybacks [1].

Core Viewpoint - As of September 30, the company reported a total of 8,011 ordinary shareholders [1] Company Summary - The company, Yirui Technology, has engaged with investors through an interactive platform, providing transparency regarding its shareholder base [1]

Core Viewpoint - The company plans to invest up to RMB 180 million in a silicon-based OLED microdisplay backplane production project through its wholly-owned subsidiary, aiming to enhance production capacity and meet market demand [1] Group 1: Investment Details - The investment will be executed by Yirui Imaging Technology (Hefei) Co., Ltd. as the implementation entity [1] - The project is expected to add a production capacity of 5,000 units per month for silicon-based OLED microdisplay backplanes [1] - The construction period for the project is estimated to be 12 months, and it is currently still under construction [1]